6,936 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by J. Goldman & Co LP

J. Goldman & Co LP acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 6,936 shares of the biopharmaceutical company's stock, valued at approximately $4,325,000.

Other large investors also recently added to or reduced their stakes in the company. SHP Wealth Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $26,000. Western Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $26,000. Titan Wealth CI Ltd bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at about $29,000. Mowery & Schoenfeld Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $29,000. Finally, Trust Co. of Vermont bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $29,000. 83.31% of the stock is owned by institutional investors.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: An analysis titled “Regeneron: Why I Still See Upside After the Rally” reflects a continued bullish view of REGN’s long-term prospects following its recent advance. Regeneron: Why I Still See Upside After the Rally
• Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day short-interest ratio. However, the figures appear incomplete or erroneous, making them unsuitable as a meaningful trading signal.
• Negative Sentiment: Several law firms publicized a securities-fraud class action tied to Regeneron’s Phase 3 melanoma-therapy trial failure. The trial disclosure reportedly triggered a sharp selloff and erased approximately $11 billion in market value; the lawsuit alleges investors were harmed by inadequate or misleading disclosures. A September 14, 2026 deadline applies to investors seeking lead-plaintiff status. Notices were issued by Hagens Berman, Pomerantz, SueWallSt, and Portnoy Law.
• Negative Sentiment: Additional law firms, including Faruqi & Faruqi, Schall Brown & Schwartz, and Levi & Korsinsky, reiterated the pending litigation and encouraged affected shareholders to participate. The repeated announcements increase near-term legal and reputational overhang, although they do not represent new operating developments. Faruqi & Faruqi notice

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the transaction, the director directly owned 603 shares of the company's stock, valued at approximately $482,400. This trade represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the company's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,400 shares of company stock worth $1,090,030 over the last three months. 6.97% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on REGN. Royal Bank Of Canada raised their price objective on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a "sector perform" rating in a research note on Friday, July 31st. Wall Street Zen upgraded Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 15th. Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a "hold" rating in a research report on Wednesday, July 29th. Piper Sandler reduced their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating for the company in a research note on Thursday, July 9th. Finally, Leerink Partners boosted their price objective on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a "market perform" rating in a research report on Monday, August 17th. Sixteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $801.70.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $833.56 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $847.00. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The stock has a market cap of $85.82 billion, a P/E ratio of 20.60, a PEG ratio of 1.41 and a beta of 0.22. The company's 50-day simple moving average is $705.74 and its 200 day simple moving average is $717.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the previous year, the business earned $12.81 earnings per share. The company's quarterly revenue was up 16.7% on a year-over-year basis. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source